Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

NCT06716138 is registered in ClinicalTrials.gov with Avistone Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06716138
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06716138 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS03 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
Lead sponsor
Avistone Biotechnology Co., Ltd.
Phase
Phase 1
Overall status
Recruiting
Start date
March 6, 2025
Completion date
March 30, 2029
Enrollment
96 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced or metastatic solid tumors harboring a ros1 or ntrk alteration